Featured News
AMPEL BioSolutions’ Precision Medicine Breakthrough Predicts Drug Options with RNA Analytics & Machine Learning
AMPEL on Bloomberg Markets
Lupus, coronary artery disease share genetic risk factors; data may lead to early testing
Local company unveils blood test to find treatments for chronic pain
Local company unveils blood test to find treatments for chronic pain
AMPEL BioSolutions Enters MDx Market With Lupus, Dermatology Gene Expression Assays
COMPANY
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
PLATFORM
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
PRODUCTS
New blood test could prevent premature death from heart attacks and stroke
You won’t find test tubes or chemicals at Ampel Biosolutions. Instead, the company uses computers to study huge amounts of medical information – to identify genes responsible for auto-immune, kidney, skin, neurologic and infectious diseases. Now, the firm says it’s got a blood test for cardiovascular events at an early age.
New Test Helps Predict Heart Disease in Lupus Patients
AMPEL BioSolutions has announced that its genetic precision medicine test for lupus patients could predict heart disease and provide decision support for prophylactic therapies.
Early Genetic Testing Predicts Heart Disease and Novel Therapies for Women with Lupus
AMPEL BioSolutions today announced a genetic precision medicine test for lupus patients that could save lives by predicting heart disease before it happens and providing decision support for prophylactic therapies.
Charlottesville company creates early genetic test to predict heart disease
It’s a breakthrough discovery for the first-time identifying risk factors in inflammation and the immune system that lead to cardiovascular events. Outside the traditional risk factors of smoking, high fat diet and sedentary lifestyle. Cardio Gene could be a game changer
In Conversation: Dr. Amrie Grammer, Co-founder, President and Chief Scientific Officer, AMPEL Biosolutions
These are exciting times for the AMPEL team. BioBuzz thought it was a great time to catch up with AMPEL’s Co-founder, President, and Chief Scientific Officer Dr. Amrie Grammer to discuss her founder’s journey and AMPEL’s promising future.
Genomic tests help doctors treat COVID-19 and long COVID
With many COVID-19 treatments now available, a simple blood test can show doctors the best route to take. Charlottesville’s AMPEL BioSolutions says it can predict and detect the severity of a COVID-19 infection, as well as how to help a patient through its new genomic test called CovGENE.
PARTNERS
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.